ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0426

T-Cell Receptor (TCR) Sequencing Reveals Decreased Diversity and Clonotypic Expansion of T-cells in Relapsing Polychondritis (RP)

Emily Rominger1, Sufia Bakshi2, Emily Rose3, Marcela Ferrada3, Peter C. Grayson4, Robert Colbert5 and Keith Sikora6, 1Systemic Autoimmunity Branch, Vasculitis Translational Research Program, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, 2National Institutes of Health, Bethesda, MD, 3Systemic Autoimmunity Branch, Vasculitis Translational Research Program, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, 4Systemic Autoimmunity Branch, National Institutes of Health, NIAMS, Bethesda, MD, 5Pediatric Clinical Trials Unit and Office of Clinical Director, NIAMS, NIH, Bethesda, MD, 6National Institutes of Health Clinical Center, Bethesda, MD

Meeting: ACR Convergence 2020

Keywords: autoantigens, Bioinformatics, cartilage, genetics, T Cell

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Friday, November 6, 2020

Title: Vasculitis – Non-ANCA-Associated & Related Disorders Poster I

Session Type: Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Relapsing polychondritis (RP) is a rare, systemic inflammatory disease characterized by recurrent inflammation of cartilaginous structures, including the nose/ears, joints, and trachea. The etiology of this life-threatening and disabling disease is currently unknown and little is known about its pathogenesis. HLA association evidence supports T-cell involvement in RP; however, the extent of T-cell involvement is incompletely understood. Previous studies demonstrate that TCR repertoire diversity is decreased in individuals with autoimmune diseases, such as rheumatoid arthritis and type 1 diabetes. Here we study the TCR repertoire of individuals with RP to identify potential disease-causing clones, which may provide critical knowledge in uncovering disease etiology, serve as a biomarker, or influence treatment decisions.

Methods: Peripheral blood leukocyte DNA was collected from 13 patients with highly active RP, and TCR-β chains were sequenced by Adaptive Biotechnologies. 3 samples containing a dominant clone were re-sequenced at a time of reduced disease activity. 13 age and sex matched healthy controls were obtained from the ImmuneACCESS public database. Data was analyzed using ImmunoSEQ Analyzer to quantify Productive Entropy, Max Productive Frequencies, Differential Abundance, and TCR- β chain V family gene usage. Frequencies were compared using the Mann-Whitney U test. Physician global assessment (PGA) was used to determine disease activity in a subset of the patients.

Results: Productive Entropy values were significantly lower in patients with RP compared to healthy controls (median 15.73 vs 16.86, P=0.0015), indicating a less diverse TCR repertoire in patients with RP. 3 patients had unique dominant clones with Max Productive Frequencies over 5 % (range 5.68-10.71%). In 2 of these patients Productive Entropy values increased in parallel with improvement in PGA scores (12.316 to 12.8916 and 14.1600 to 15.5207 respectively) and Max Productive Frequencies of dominate clones decreased (5.675% to 4.961% and 10.712% to 7.476% respectively). Additionally, 3 TCR- β chain variable (V) expansions were detected for Vβ9, Vβ19, and Vβ20 families that were not expanded in controls.

Conclusion: TCR repertoire is less diverse in patients with RP compared to healthy controls. Expanded TCR- β chain V families and dominant clones not expressed in healthy controls may provide insights to antigenic drivers of RP. Further, the TCR repertoire may be less diverse during active disease compared to lower disease activity. Based upon these findings, we intend to confirm the trends in a larger cohort of patients, make comparisons to immunophenotypes and clinical associations, and detect possible antigens by clustering TCRs with conserved CDR3 and V family motifs.


Disclosure: E. Rominger, None; S. Bakshi, None; E. Rose, None; M. Ferrada, None; P. Grayson, None; R. Colbert, Eli Lilly and Company, 2, Eli Lilly and Company, 9; K. Sikora, None.

To cite this abstract in AMA style:

Rominger E, Bakshi S, Rose E, Ferrada M, Grayson P, Colbert R, Sikora K. T-Cell Receptor (TCR) Sequencing Reveals Decreased Diversity and Clonotypic Expansion of T-cells in Relapsing Polychondritis (RP) [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/t-cell-receptor-tcr-sequencing-reveals-decreased-diversity-and-clonotypic-expansion-of-t-cells-in-relapsing-polychondritis-rp/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/t-cell-receptor-tcr-sequencing-reveals-decreased-diversity-and-clonotypic-expansion-of-t-cells-in-relapsing-polychondritis-rp/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology